Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

Experimental Neurology

Volumn 192, Issue 1, 2005, Pages 73-78

  Bibbiani, Francesco ^a   Costantini, Lauren C ^b   Patel, Raj ^b   Chase, Thomas N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Titan Pharmaceuticals Inc   (United States)

Author keywords

Apomorphine; Dopamine; Dyskinesia; Ethylene vinyl Acetate; Implant; Nigra; Parkinson's disease; Polymeric; Striatum; Subcutaneous

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ETHYLENE VINYL ACETATE COPOLYMER; LEVODOPA; SHORT ACTING DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DYSKINESIA; MALE; MONKEY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

EID: 13444273340     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.11.013     Document Type: Article

References (36)

1. J.E. Ahlskog, M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 3 2001 448 458
2. F. Baronti, M.M. Mouradian, T.L. Davis, M. Giuffra, G. Brughitta, K.E. Conant, T.N. Chase Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease Ann. Neurol. 6 1992 776 781
3. E. Bezard, J.M. Brotchie, C.E. Gross Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nat. Rev., Neurosci. 8 2001 577 588
4. F. Bibbiani, J.D. Oh, T.N. Chase Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 10 2001 1829 1834
5. F. Bibbiani, J.D. Oh, J.P. Petzer, N. Castagnoli, J-F. Chen, M.A. Schwarzchild, T.N. Chase A2A antagonist prevents dopamine agonist-induced motor complications in animal models of PD Exp. Neurol. 1 2003 285 294
6. D. Bravi, M.M. Mouradian, J.W. Roberts, T.L. Davis, Y.H. Sohn, T.N. Chase Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms Ann. Neurol. 1 1994 27 31
7. T.N. Chase Striatal plasticity and extrapyramidal motor dysfunction Parkinsonism Relat. Disord. 5 2004 305 313 (Review)
8. T.N. Chase, J.D. Oh Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications Ann. Neurol. 4 2000 S122 S129
9. T.N. Chase, J.D. Oh Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism Trends Neurosci. 10 2000 S86 S91 (Suppl.)
10. T.N. Chase, F. Baronti, G. Fabbrini, I.J. Heuser, J.L. Juncos, M.M. Mouradian Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Review Neurology 39 Suppl. 2 1989 7 10
11. R.B. Dewey Jr., D.M. Maraganore, J.E. Ahlskog, J.Y. Matsumoto Intranasal apomorphine rescue therapy for parkinsonian "off" periods Clin. Neuropharmacol. 3 1996 193 201
12. A. Hadj Tahar, L. Gregoire, E. Bangassoro, P.J. Bedard Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys Clin. Neuropharmacol. 4 2000 195 202
13. P Jenner Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments J. Neurol. 247 2000 SII43 SII50
14. J.L. Juncos, T.M. Engber, R. Raisman, Z. Susel, F. Thibaut, A. Ploska, Y. Agid, T.N. Chase Continuous and intermittent levodopa differentially affect basal ganglia function Ann. Neurol. 5 1989 473 478
15. R. Langer, J. Folkman Polymers for the sustained release of proteins and other macromolecules Nature 263 1976 797 800
16. G.J. Lesser, S.A. Grossman, K.W. Leong, H. Lo, S. Eller In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain Pain 2-3 1996 265 272
17. P.A. LeWitt Subcutaneously administered apomorphine: pharmacokinetics and metabolism Neurology 62 Suppl. 4 2004 S8 S11
18. A.J. Manson, H. Hanagasi, K. Turner, P.N. Patsalos, P. Carey, N. Ratnaraj, A.J. Lees Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations Brain 124 2001 331 340
19. A.J. Manson, K. Turner, A.J. Lees Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease Investigator's Drug Brochure Mov. Disord. vol. 6 2002 Titan Pharmaceuticals 1235 1241
20. E. Martignoni, G. Riboldazzi, D. Calandrella Riva N. motor complications of Parkinson's disease Neurol. Sci. 24 2003 S27 S29
21. E. Miyawaki, K. Lyons, R. Pahwa, A.I. Troster, J. Hubble, D. Smith, K. Busenbark, D. McGuire, D. Michalek, W.C. Koller Motor complications of chronic levodopa therapy in Parkinson's disease Clin. Neuropharmacol. 6 1997 523 530
22. J.L. Montastruc, O. Rascol, J.M. Senard, G. Houin, A. Rascol Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? J. Neural Transm., Suppl. 45 1995 157 161
23. M. Morissette, M. Goulet, J.J. Soghomonian, P.J. Blanchet, F. Calon, P.J. Bedard, T. Di Paolo Preproenkephalin mRNA expression in the caudate-putamen of MPTP primates after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy Brain Res. Mol. Brain Res. 49 1997 55 62
24. M.M. Mouradian, I.J. Heuser, F. Baronti, T.N. Chase Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease Ann. Neurol. 1 1990 18 23
25. D. Muguet, E. Broussolle, G. Chazot Apomorphine in patients with Parkinson's disease Biomed. Pharmacother. 4 1995 197 209
26. C. Neef, T. van Laar Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease Clin. Pharmacokinet. 3 1999 257 271
27. W. Olanow, A.H. Schapira, O. Rascol Continuous dopamine-receptor stimulation in early Parkinson's disease Trends Neurosci. 23 2000 S117 S126
28. L. Ostergaard, L. Werdelin, P. Odin, O. Lindvall, E. Dupont, P.B. Christensen, E. Boisen, N.B. Jensen, S.H. Ingwersen, M. Schmiegelow Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study J. Neurol. Neurosurg. Psychiatry 6 1995 681 687
29. S.M. Papa, T.M. Engber, A.M. Kask, T.N. Chase Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration Brain Res. 662 1994 69 74
30. W. Poewe, G.K. Wenning Apomorphine: an underutilized therapy for Parkinson's disease Mov. Disord. 5 2000 789 794
31. P. Pollak, A.L. Benabid, P. Limousin, C.L. Gervason, E. Jeanneau-Nicolle External and implanted pumps for apomorphine infusion in parkinsonism Acta Neurochir., Suppl. 58 1993 48 52
32. W. Raasch, C. Slotty, P. Dominiak In vitro and in vivo long term release of apomorphine from polymer matrices Jpn. J. Pharmacol. 1 2000 36 43
33. S. Skirboll, J. Wang, I. Mefford, J. Hsiao, K.S. Bankiewicz In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis Exp. Neurol. 2 1990 187 193
34. L.A. Smith, M.J. Jackson, M.J. Hansard, E. Maratos, P. Jenner Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure Mov. Disord. 5 2003 487 495
35. G.K. Wenning, S. Bosch, E. Luginger, M. Wagner, W. Poewe Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease Adv. Neurol. 80 1999 545 548
36. J. White Probuphine for the Treatment of Opiate Addiction-Preliminary Results International Society of Addiction Medicine Mtg 2003